Objective-Leukotriene B 4 (LTB 4 ), a product of the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism, has been implicated in atherosclerosis. However, the molecular mechanisms for the atherogenic effect of LTB 4 are not well understood. This study is to determine candidate mechanisms. Method and Results-Primary human monocytes were treated with LTB 4 and the supernatant was analyzed for cytokine/chemokine production by an immuno-protein array. This analysis revealed a strong increase of the monocyte chemoattractant protein-1 (MCP-1), a proinflammatory cytokine. 
L eukotriene B 4 (LTB 4 ), a product of the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism, is a potent chemoattractant and proinflammatory mediator involved in the pathogenesis of several inflammatory diseases including atherosclerosis. [1] [2] [3] The biological effects of LTB 4 are mediated by activation of 2 G-protein coupled receptors, the high-affinity receptor BLT 1 and the low-affinity receptor BLT 2 . 4, 5 Studies with BLT 1 -specific and BLT 2 -specific antagonists demonstrate that BLT 1 activation is involved in inflammation and immunologic effects of LTB 4 , whereas the function of BLT 2 is not yet well defined. 6 
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Recent studies suggest a strong link between LTB 4 pathways with atherosclerosis. For example, human atherogenic plaques produce LTB 4 , 7 and expression of both BLT 1 and BLT 2 increases with the progression of atherosclerotic lesions. 8 Treatment of atherosclerosis-prone mice (apolipoprotein E [ApoE] or low-density lipoprotein receptor [LDLR]-deficient mice) with the BLT 1 -specific antagonist CP-105,696 9,10 markedly decreased lesion size. 11 Interestingly, the anti-atherogenic effects of CP-105,696 were diminished in mice deficient in the chemoattractant monocyte chemotactic protein-1 (MCP-1), 11 indicating a critical role for MCP-1 in mediating the LTB 4 atherogenic signals.
MCP-1 is a prototype of the C-C chemokine ␤ subfamily and exhibits the most potent chemotactic activity for monocytes. 12 Overexpression of MCP-1 contributes to the development of atherosclerosis in mouse models. 13 Deficiency of either MCP-1 or its cognate high-affinity receptor C-C chemokine receptor 2 (CCR2) results in a marked decrease in atheromas and fewer monocytes in vascular lesions. 14, 15 Additionally, therapeutic gene transfer of a dominantnegative MCP-1 mutant attenuated the development of early atherosclerosis and also limited progression of preexisting atherosclerotic lesions in ApoE-null mice. 16 Despite the critical role played by LTB 4 in atherogenesis, the molecular mechanisms for these activities are poorly understood. In this study, we investigated specifically whether LTB 4 regulates MCP-1 production in primary human monocytes to broaden the mechanistic understanding for LTB 4 -induced atherosclerosis. Our study shows that LTB 4 induced MCP-1 protein by several hundred-fold in primary human monocytes. LTB 4 induced MCP-1 mRNA by 500-fold to 600-fold, suggesting that LTB 4 -induced MCP-1 protein expression was accomplished by a transcriptional mechanism. The BLT 1 -specific antagonist CP-105,696 effectively blocked this induction, indicating that this event is mediated through the BLT 1 signaling pathway. We further demonstrated that inhibitors of ERK1/2 or JNK MAPK abolished this induction. Additionally, we showed that LTB 4 increased NF-B DNA binding activity, which was blocked by CP-105,696. Taken together, these results suggest that the pathway for LTB 4 -induced MCP-1 production involves activation of ERK1/2 or JNK and activation of NF-B. The LTB 4 -induced MCP-1 expression in primary monocytes may play a pivotal role in the atherogenicity of LTB 4 .
Methods

Materials
The following reagents were obtained from Invitrogen: DMEM and RPMI-1640 medium, fetal bovine serum, and fetal calf serum, and TRIZOL reagents. The RayBio™ Human Cytokine Array V was obtained from RayBiotech, Inc. The enriched human monocytes were purchased from Biological Specialty Inc. The Calcium ϩϩ Assay Kit was obtained from Molecular Devices Corporation. The leukotrienes B 4 , C 4 , D 4 , and E 4 were from BIOMOL. CP-105,696 can be made according to the procedure of Koch et al. 17 The human MCP-1 Quantikine kit was purchased from R&D Systems, Inc. SB202190 was purchased from Calbiochem, and PD98059 was from Cell Signaling. U0126 and Curcumin were from Sigma. TaqMan reagents for cDNA synthesis and real-time polymerase chain reaction (PCR) (TaqMan), TaqMan oligonucleotide primers and probes for human MCP-1, and human 18S RNA were purchased from Applied Biosystems. Human BLT 1 cDNA was a gift from Dr. Takao Shimizu at University of Tokyo.
Isolation and Treatment of Primary Human Monocytes
Ten milliliters of lymphocyte separation medium (LSM/Ficoll) was slowly added to 40 mL of the enriched human monocytes from Biological Specialty Inc, and the mixture was spun at 600g for 20 minutes. The peripheral blood mononuclear cell layer was collected and filled with PBS to 50 mL, and then spun at 1000 rpm for 5 minutes. The cell pellet was resuspended in 5 mL RPMI-1640 medium containing 10% fetal calf serum. Sheep red blood cells were added to the pellet and incubated for 15 minutes at 37°C followed by centrifugation at 1000 rpm for 5 minutes. The pellet was kept at Ϫ20°C for 6 minutes, and then was gently resuspended in 25 mL of phosphate-buffered saline. The cells were further purified with 10 mL LSM/Ficoll by repeating the same steps as described. The mononuclear layer at the interface was collected. The red blood cells were lysed if necessary. Monocytes were resuspended in 50 mL of RPMI-1640 medium containing10% fetal calf serum.
The primary monocytes in RPMI-1640 medium were pelleted and resuspended in Hank's balanced salt solution (HBSS) buffer (with calcium and magnesium) containing 2% Pen/Strep and 1% heat-inactivated fetal bovine serum. The cells were seeded in 24-well plates at a density of 2ϫ10 6 cells per well and incubated with various concentrations of LTB 4 , LTC 4 , LTD 4 , LTE 4 or carbamyl plateletactivating factor (c-PAF). For inhibitor studies, monocytes were pretreated for 30 minutes with CP-105,696 (LTB 4 receptor antagonist), PD98059 (ERK1/2 MAPK inhibitor), U0126 (ERK1/2 MAPK inhibitor, 10 mol/L), curcumin (JNK MAPK inhibitor, 10 mol/L), and SB202190 (p38 MAPK inhibitor, 1 mol/L) before the addition of 30 nM LTB 4 . Unless specified, cells were treated overnight before the medium was collected and centrifuged to remove any residual cells. The cell-free supernatant was stored at Ϫ80°C for MCP-1 determination, and cells were dissolved in TRIZOL reagent for total RNA isolation.
Analysis of Human Cytokine Array and MCP-1 Determination
The human cytokine array studies were conducted using the RayBio TM Human Cytokine Array V kit following the manufacturer's instructions. Primary human monocytes were treated overnight with ethanol or 60 nM LTB 4 , and the cell-free supernatant was collected. One milliliter of each sample was used for analysis. The human MCP-1 concentrations were determined by the Quantikine kit according to the manufacturer's instructions.
The Fluorometric Imaging Plate Reader Assay
The fluorometric imaging plate reader (FLIPR) assay was used to confirm the BLT 1 antagonist activity of CP-105,696. HEK 293T cells stably overexpressing BLT 1 (Zhao et al, unpublished data) were seeded at a density of 22000 cells/well in 384-well plates 24 hours before the assay. The FLIPR assays were performed using the Calcium ϩϩ Assay Kit from Molecular Devices Corporation according to manufacturer's instructions. Briefly, 10 mL of HBSS with 20 mmol/L HEPES were added to Component A from the kit to make a 10ϫ loading dye. Then probenecid (Sigma P-8761) was freshly added to the 10ϫ loading dye. To each well, 25 L of the 1ϫ loading dye was added and incubated with cells for 1 hour at 37°C. CP-105,696 was diluted with 1ϫ HBSS/HEPES/ probenecid buffer from which 25 L was added 5 minutes before the addition of 25 L of LTB 4 at a final concentration of 5 nM. Plates were then read for 5 more minutes. Maximal peak values were used for calculation.
Electrophoretic Mobility-Shift Assay
NF-B DNA binding activity was determined using Gel Shift Assay Systems kits from Promega following manufacture's instruction. Briefly the nuclear extract was isolated from primary human monocytes treated with 30 nM LTB 4 , 30 nM LTC 4 , or 30 nM LTB 4 plus 3 nM CP-105,696 overnight. Nuclear proteins (6 g) were added to the 1ϫ binding buffer provided with the kits in the presence or absence of a 100-fold excess of the unlabeled NF-B oligonucleotide (specific competitor) or the AP-1 oligonucleotide (nonspecific competitor) and incubated at room temperature for 10 minutes. The 32 P-labeled probe (5Ј-AGT TGA GGG GAC TTT CCC AGG C-3Ј) was then added to the reaction and incubated at room temperature for 20 minutes. The protein-DNA complex was resolved on a 4% acrylamide gel, which was then dried and exposed for autoradiography.
RNA Isolation and Real-Time Quantitative PCR
Total RNA was extracted from the treated primary human monocytes using the TRIZOL reagent according to the manufacturer's instructions. Reverse-transcription reactions and TaqMan PCRs were performed according to the manufacturer's instructions (Applied Biosystems). Sequence-specific amplification was detected with an increased fluorescent signal of FAM (reporter dye) during the amplification cycles. Amplification of human 18S RNA was used in the same reaction of all samples as an internal control. Gene-specific mRNA was subsequently normalized to 18S RNA. Levels of human MCP-1 mRNA were expressed as fold difference of compoundtreated cells against vehicle-treated cells.
Oligonucleotide primers/probe for human MCP-1 were designed using the Primer Express program and were synthesized by Applied Biosystems. These sequences (5Ј to 3Ј) are as follows: forward primer (CAAGCAGAAGTGGGTTCAGGAT), probe (6FAM-CATGGACCACCTGGACAAGCAAACC-TAMRA), and reverse primer (AGTGAGTGTTCAAGTCTTCGGAGTT).
Results
LTB 4 Strongly Increases MCP-1 Production in Primary Human Monocytes
To determine whether LTB 4 can regulate expression of proinflammatory cytokines/chemokines, primary human monocytes were treated with 60 nM LTB 4 overnight, and the cell-free supernatant was collected and hybridized with an immunoblot array that contains 79 human cytokines/chemokines. Compared with the vehicle-treated control ( Figure 1A ), LTB 4 induced expression of MCP-1 protein by several hundred-fold ( Figure 1B ). In addition, LTB 4 treatment also resulted in modest changes of other cytokines/chemokines including increases in placental growth factor and transforming growth factor (TGF) B3 (TGF-B3) and a decrease in macrophage inflammatory protein-1␤ (MIP-1␤) ( Figure 1B ). This study solely focused on the investigation of LTB 4 -induced MCP-1 expression.
Follow-up experiments were conducted to confirm the observation of LTB 4 -induced MCP-1 production. In these experiments, primary monocytes were treated overnight with 30 nM LTB 4 , as well as with 30 nM LTC 4 , LTD 4 , or LTE 4 (to assess the effect of cysteinyl leukotrienes on MCP-1 expression), and MCP-1 in the supernatant was quantified by an enzyme-linked immunosorbent assay. An agonist of plateletactivating factor (PAF), c-PAF, which is a known inducer of MCP-1, 18 was included as a positive control. Consistent with the results in the immunoblot array, LTB 4 increased MCP-1 protein by Ͼ200-fold ( Figure 1C ). In contrast, the cysteinyl leukotrienes C 4 , D 4 , and E 4 did not significantly regulate MCP-1 expression ( Figure 1C ). Similar to the previous reports, 18 1 mol/L c-PAF increased MCP-1 protein by 50-fold ( Figure 1C) . LTB 4 robustly increased MCP-1 protein in a dosedependent manner with a half-maximum stimulation (EC 50 ) value between 3 and 10 nM (Figure 2A ). Primary human monocytes were treated with vehicle (ethanol) or 30 nM LTB 4 for 1, 4, 16, 24, and 36 hours to define the time kinetics for LTB 4 -induced MCP-1 production. LTB 4 increased MCP-1 protein in a time-dependent fashion, and significant increase was observed from 16 to 36 hours ( Figure 2B ). In the vehicle-treated cells, the basal level of MCP-1 was also slightly increased with time ( Figure 2B ).
LTB 4 Induces MCP-1 Transcription
To investigate whether the increase of MCP-1 protein in supernatants resulted from an increased transcription of MCP-1, total RNA from treated primary human monocytes was extracted and the endogenous MCP-1 mRNA was determined by real-time PCR (TaqMan). Consistent with the observation that LTB 4 strongly increased MCP-1 protein, LTB 4 at 30 nM increased MCP-1 mRNA by Ͼ500-fold ( Figure 3A) , whereas the cysteinyl leukotrienes C 4 , D 4 , and E 4 did not significantly increase MCP-1 transcription ( Figure 3A) . c-PAF also increased MCP-1 mRNA by Figure 3A) . LTB 4 increased MCP-1 mRNA in a dose-dependent manner ( Figure 3B ).
30-fold to 50-fold (
CP-105,696 Effectively Blocks LTB 4 -Induced MCP Production
CP-105,696 is a synthetic BLT 1 antagonist that potently and specifically blocks LTB 4 -mediated functional responses. 9, 10 In our experiments, CP-105,696 effectively inhibited LTB 4 -stimulated calcium flux in HEK 293T cells stably expressing BLT 1 with a half-maximum inhibition (IC 50 ) value of 34 nM ( Figure 4A ). To determine whether the LTB 4 -induced MCP-1 expression is mediated by BLT 1 , primary monocytes were treated with CP-105,696 in the presence and absence of 30 nM LTB 4 , and the MCP-1 levels in the supernatant were determined by enzyme-linked immunosorbent assay. LTB 4 alone increased MCP-1 protein by 400-fold to 500-fold ( Figure 4B ), and this increase was effectively blocked by CP-105,696 in a dose-dependent manner with an IC 50 value between 0.1 and 0.3 nM ( Figure 5B ). These data suggest that the induction of MCP-1 by LTB 4 is mediated through the BLT 1 pathway.
Inhibition of ERK1/2 and/or JNK MAPKs Abolished LTB 4 -Induced MCP-1
It has been previously shown that activation of BLT 1 may result in activation of variety protein kinases. 19, 20 We asked whether ERK1/2, JNK or p38 MAPKs are involved in the LTB 4 -induced MCP-1 protein expression. Figure 5A shows that LTB 4 -induced MCP-1 expression was effectively blocked by the ERK1/2 MAPK inhibitor PD98059 in a dose-dependent fashion, and that this induction was completely abolished by PD98059 at 5 mol/L. U0126, another inhibitor of ERK1/2 MAPK, also completely blocked MCP-1 induction at 10 mol/L (Figure 5B ), indicating that activation of ERK1/2 is an essential step for LTB 4 -induced MCP-1 expression. The JNK MAPK inhibitor curcumin (10 mol/L) completely blocked this induction as well ( Figure 5B ), suggesting that activation of JNK is also necessary for the LTB 4 -induced MCP-1 expression. In contrast, the p38 MAPK inhibitor SB202190 had no effect on MCP-1 expression (data not shown), suggesting that p38 activation is not required for this signaling pathway.
LTB 4 Increases NF-B DNA Binding Activity in Primary Human Monocytes
It has been reported that NF-B plays a key role in regulating MCP-1 transcription. 21 To elucidate the molecular basis for LTB 4 -induced MCP-1 expression, we determined whether LTB 4 could increase NF-B DNA binding activity in primary human monocytes. Consistent with these results, nuclear extracts from LTB 4 -treated but not LTC 4 -treated cells showed a strong increase in NF-B DNA binding activity ( Figure 6A,  lanes 2, 3, and 5 ). Furthermore, this activity was effectively abolished by the BLT 1 antagonist CP-105,696 ( Figure 6A , lane 4). The specificity for LTB 4 -increased NF-B activity was demonstrated by competition experiments ( Figure 6B ). This NF-B activity was completely abolished by a 100-fold molar excess of unlabeled NF-B oligonucleotide ( Figure 6B , lanes 3 and 4) but was not affected by the same molar excess of an unrelated oligonucleotide ( Figure 6B, lanes 5 and 6) . In addition to NF-B, LTB 4 treatment did not significantly increase the DNA binding activity for AP-1, AP-2, CREB, and SP-1 (data not shown). Taken together, these results indicate that NF-B was activated by LTB 4 and suggest that NF-B may play an important role in LTB 4 -induced MCP-1 expression in monocytes.
Discussion
Recent biologic and genetic findings implicate that the 5-LO pathway plays a critical role in atherosclerosis. 18, [22] [23] [24] Mehrabian et al reported that heterozygotes for the 5-LO gene on the LDLR Ϫ/Ϫ background had considerably reduced aortic lesions despite hypercholesterolemia as compared with the advanced lesions of LDLR Ϫ/Ϫ mice. 25 Dwyer et al showed that variant alleles of 5-LO genes were associated with a significant increase of carotid intima thickness. 26 Most recently, Helgadottir et al demonstrated a significant association between the gene encoding 5-LO activating protein (FLAP) and myocar- dial infarction by analysis of single-nucleotide polymorphism haplotype in humans. 22 The involvement of BLT 1 signaling pathways in atherosclerosis is illustrated by the studies showing that BLT 1 gene deficiency and a BLT 1 -specific antagonist significantly reduced atherosclerosis in mouse models. 11, 27 Despite strong evidence linking LTB 4 biosynthesis and receptor pathways to atherosclerosis, the detailed molecular mechanisms for these events are not well defined. MCP-1 is one of the most potent chemotactic factors and has been shown to plays a major role in the initiation and progression of atherosclerosis. We hypothesized that the atherogenic activity of LTB 4 may, at least in part, be caused by its regulation on MCP-1 expression. Our study shows that LTB 4 strongly induces expression of MCP-1 mRNA and protein. This induction was mediated through the BLT 1 pathway. Furthermore, we demonstrate that this induction requires activation of ERK1/2 or JNK and may involve NF-B activation. These data are consistent with the observation that the anti-atherogenic effects of the BLT 1 antagonist CP-105,696 were diminished in MCP-1-deficient mice. 11 Under normal physiological conditions, the level of leukotrienes in human plasma is undetectable (Ͻ1 pg/mL). However, after activation of cells by an inflammatory stimulus, the increase of intracellular calcium would lead to a great increase of leukotriene biosynthesis. For instance, neutrophils produce 50 ng of LTB 4 /10 6 cells 28 and eosinophils produce 25 to 50 g of CysLTs/10 6 cells 29 in response to the calcium ionophore challenge. The concentration for LTB 4 -induced MCP-1 expression in this study is in a low nM range (3 to 10 nM), which may well be relevant to the pathological conditions.
It has been well established that LTB 4 is a potent chemoattractant that promotes leukocyte adherence to the vascular endothelium. Friedrich et al recently reported that LTB 4 triggers both ␤1-integrin-dependent and ␤2-integrin-dependent monocyte adhesion in equipotency with MCP-1. 30 In their study, a PI 3 kinase inhibitor (LY294002) partially blocked MCP-1-mediated but not LTB 4 -mediated cell adhesion, arguing that the chemotactic activity of LTB 4 is independent of MCP-1. However, their study only analyzed cell adhesion 1 minute after the addition of LTB 4 , but our results show that significant induction of MCP-1 production requires a longer interval of time. Thus, it is possible that the transient chemotactic activity of LTB 4 is independent of MCP-1, but a prolonged effect can be mediated or enhanced by MCP-1. It is tentative to speculate that MCP-1 and LTB 4 may trigger cell adhesion in an additive or synergistic fashion to effectively recruit monocytes into the subendothelial space, the hallmark of atherosclerosis.
This study provides evidence demonstrating for the first time to our knowledge that LTB 4 strongly induces MCP-1 production in primary human monocytes. The increased MCP-1 may then lead to a great amplification of the proinflammatory effect of LTB 4 . Data reported by Matsukawa et al suggested that MCP-1 increases LTB 4 production in mice. 31 Taken together, it is likely that in atherosclerotic lesions, LTB 4 and MCP-1 amplify each other by a feed-forward loop leading to a greatly accelerated initiation and progression of the disease. This study not only enhances the mechanistic understanding of the role of LTB 4 in atherogenesis but also adds evidence to the idea that the LTB 4 biosynthetic and receptor signaling pathways may be attractive targets for the therapeutic intervention of atherosclerosis.
During preparation of this manuscript, a publication 27 describing gene expression in rat basophilic leukemia cells (RBL-2H3) expressing the human BLT 1 showed that MCP-1 was one of the genes most robustly induced by LTB 4 . 2) . Arrows indicate the specific DNA-protein complex.
